Skip to main content
SpringerLink
Log in

Cisplatin-Induced Hearing Loss

  • Chapter
  • First Online:
Book cover Translational Research in Audiology, Neurotology, and the Hearing Sciences

Part of the book series: Springer Handbook of Auditory Research ((SHAR,volume 58))

Abstract

For decades, cisplatin chemotherapy has significantly increased survival in numerous cancer patient populations. However, cisplatin treatment results in severe adverse side effects including nephrotoxicity, neurotoxicity, radiation-induced oral mucositis, ototoxicity, and permanent hearing loss. Protection from cisplatin’s adverse side effects has therefore been a translational research focus for many years. This chapter discusses cisplatin’s historical discovery, its clinical application, and cisplatin-induced ototoxicity mechanisms. The chapter then reviews current translational research to protect from cisplatin-induced hearing loss, including clinical behavioral and objective monitoring techniques; adult and pediatric grading scales implemented to measure and identify cisplatin-induced ototoxicity; and potential otoprotective mechanisms that are currently tested to prevent cisplatin-induced ototoxicity in animals and clinical trials. Finally, the chapter reviews potential clinical trial funding and the steps required by the FDA, including the extensive investigational new drug (IND) application, to test otoprotective agents for protection from cisplatin-induced hearing loss. At the chapter’s end, readers should acquire general knowledge underlying cisplatin’s intricate history and clinical cisplatin use and understand the steps required to design and perform translational otoprotection studies to prevent cisplatin-induced ototoxicity and permanent hearing loss.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alderen, R., Hall, M., & Hambley, T. (2006). The discovery and development of cisplatin. Journal of Chemical Education, 83(5), 728–734.

    Google Scholar 

  • American Academy of Audiology (AAA), Durrant, J., Campbell, K., Fausti, S., Guthrie, O., et al. (2009). American Academy of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity monitoring. www.Audiology.org, pp. 1–25.

    Google Scholar 

  • American Speech-Language-Hearing Association (ASHA). (1987). Calibration of speech signals delivered via earphones. ASHA, 29(6), 44–48.

    Google Scholar 

  • American Speech-Language-Hearing Association (ASHA). (1988). Guidelines for determining threshold level for speech. ASHA, (30)3, 85–89.

    Google Scholar 

  • American Speech–Language–Hearing Association (ASHA). (1994). Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36(Suppl. 12), 11–19.

    Google Scholar 

  • Anderson, J. M., & Campbell, K. (2015). Assessment of interventions to prevent drug-induced hearing loss. In J. M. Miller, C. G. Le Prell, & L. P. Rybak (Eds.), Oxidative stress in applied basic research and clinical practice: Free radicals in ENT pathology (pp. 243–269). New York: Humana Press.

    Google Scholar 

  • Baik, M., Freisner, R., & Lippard, S. (2003). Theoretical study of cisplatin binding to purine bases: Why does cisplatin prefer guanine over adenine? Journal of the American Chemistry Society, 125(46), 14082–14092.

    Google Scholar 

  • Baldew, G. S., McVie, J. G., van der Valk, M. A., Los, G., de Goeij, J. J., & Vermeulen, N. P. (1990). Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. Cancer Research, 50(21), 7031–7036.

    Google Scholar 

  • Benedetti Panici, P., Greggi, S., Scambia, G., Baiocchi, G., Lomonaco, M., et al. (1993). Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up. International Journal of Gynecological Cancer, 3, 44–53.

    Google Scholar 

  • Bhattacharyya, T. K., & Dayal, V. S. (1984). Ototoxicity and noise-drug interaction. Journal of Otolaryngology, 13, 361–366.

    Google Scholar 

  • Bierbach, U., Qu, Y., Hambley, T., Peroutka, J., Nguyen, H., et al. (1999). Synthesis, structure, biological activity, and DNA binding of platinum(II) complexes of the type trans-[PtCl(2)(NH(3))L] (L = planar nitrogen base). Effect of L and cis/trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorganic Chemistry, 38(15), 3535–3542.

    Google Scholar 

  • Blackwell, D. L., Lucas, J. W., & Clarke, T. C. (2014). Summary health statistics for U.S. adults: National Health Interview, 2012 Survey. National Center for Health Statistics. Vital Health Statistics, 10(260).

    Google Scholar 

  • Bokemeyer, C., Berger, C., Hartmann, J., Kollmannsberger, C., Schmoll, H., et al. (1998). Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. British Journal of Cancer, 77, 1355–1362.

    Google Scholar 

  • Boulikas, T., & Vougiouka, M. (2004). Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncology Reports, 11, 559–595.

    Google Scholar 

  • Brock, P. R., Bellman, S. C., Yeomans, E. C., Pinkerton, C. R., & Pritchard, J. (1991). Cisplatin ototoxicity in children: A practical grading system. Medical and Pediatric Oncology, 19(4), 295–300.

    Google Scholar 

  • Brock, P. R., Knight, K. R., Freyer, D. R., Campbell, K. C., Steyger, P. S., et al. (2012). Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston Ototoxicity Scale. Journal of Clinical Oncology, 30(19), 2408–2417.

    Google Scholar 

  • Butler, D. (2008). Translational research: Crossing the valley of death. Nature, 453(7197): 840–842.

    Google Scholar 

  • Campbell, K. C. M. (2004). Audiologic monitoring for ototoxicity. In P. Roland & J. Rutka (Eds.), Ototoxicity (pp. 153–160) New York: BC Decker.

    Google Scholar 

  • Campbell, K. C. M., & Durrant, J. D. (1993). Audiologic monitoring for ototoxicity. Otolaryngology Clinics of North America, 26, 903–914.

    Google Scholar 

  • Campbell, K. C. M., & Le Prell, C. G. (2012). Potential therapeutic agents. Seminars in Hearing, 32(3), 281–296.

    Google Scholar 

  • Campbell, K. C., Rybak, L. P., Meech, R. P., & Hughes, L. (1996). D-Methionine provides excellent protection from cisplatin ototoxicity in the rat. Hearing Research, 102(1–2), 90–98.

    Google Scholar 

  • Campbell, K. C., Meech, R. P., Rybak, L. P., & Hughes, L. F. (1999). D-Methionine protects against cisplatin damage to the stria vascularis. Hearing Research, 138(1–2), 13–28.

    Google Scholar 

  • Campbell, K. C. M., Kalkanis, J., & Glatz, F. R. (2000). Ototoxicity: Mechanisms, protective agents, and monitoring. Current Opinions in Otolaryngology & Head and Neck Surgery. 8, 436–440.

    Google Scholar 

  • Campbell, K. C. M., Kelly, E., Targovnik, N., Hughes, L. F., Van Saders, C., et al. (2003). Audiologic monitoring for potential ototoxicity in a Phase I clinical trial of a new glycopeptide antibiotic. Journal of the American Academy of Audiology: Special Edition on Ototoxicity, 14(3), 157–169.

    Google Scholar 

  • Campbell, K. C. M., Nayar, R., Borgonha, S., Hughes, L. F., Rehemtulla, A., et al. (2009). Oral D-methionine (MRX-1024) significantly protects against cisplatin-induced hearing loss: A phase II study in humans. Abstracts of the Association for Research in Otolaryngology, 32, 7.

    Google Scholar 

  • Cancer Therapy Evaluation Program (CTEP). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed August 6, 2010.

  • Carhart, R., & Jerger, J. F. (1959). Preferred method for clinical determination of pure-tone thresholds. Journal of Speech and Hearing Disorders, 24, 330–345.

    Google Scholar 

  • Casares, C., Ramirez-Camacho, R., Trinidad, A., Roldan, A., Jorge, E., & Garcia-Berrocal, J. (2012). Reactive oxygen species in apoptosis induced by cisplatin: Review of physiopathological mechanisms in animal models. European Archives of Otorhinolaryngology, 269, 2455–2459.

    Google Scholar 

  • Chang, K. W. (2011). Clinically accurate assessment and grading of ototoxicity. Laryngoscope, 121(12), 2649–2657.

    Google Scholar 

  • Chang, K. W., & Chinosornvatana, N. (2010). Practical grading system for evaluating cisplatin ototoxicity in children. Journal of Clinical Oncology, 28(10), 1788–1795.

    Google Scholar 

  • Church, M. W., Kaltenbach, J. A., Blakley, B. W., & Burgio, D. L. (1995). The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hearing Research, 86(1–2), 195–203.

    Google Scholar 

  • Cloven, N. G., Re, A., McHale, M. T., Burger, R. A., DiSaia, P. J., et al. (2000). Evaluation of D-methionine as a cytoprotectant in cisplatin treatment of an animal model for ovarian cancer. Anticancer Research, 20(6B), 4205–4209.

    Google Scholar 

  • Coller, B. S., & Califf, R. M. (2009). Traversing the valley of death: A guide to assessing prospects for translational success. Science Translational Medicine, 1(10):1–11.

    Google Scholar 

  • Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference Accessed May 21, 2015.

  • Duval, M., & Daniel, S. J. (2012). Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. Journal of Otolaryngology–Head and Neck Surgery, 41(5), 309–315.

    Google Scholar 

  • Fausti, S., Schechter, M. A., Rappaport, B. Z., Frey, R. H., & Mass, R. E. (1984). Early detection of cisplatin ototoxicity: Selected case reports. Cancer, 53, 224–231.

    Google Scholar 

  • Fausti, S. A., Henry, J. A., Helt, W. J., Phillips, D. S., Frey, R. H., et al. (1999). An individualized, sensitive frequency range for early detection of ototoxicity. Ear and Hearing, 20(6), 497–505.

    Google Scholar 

  • Food and Drug Administration Investigational New Drug Application. fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm.

  • Glattke, T., & Robinette, M. (2007). Otoacoustic emissions. In Roeser, R., Valente, M., and Hosford-Dunn, H. (Eds.), Audiology: Diagnosis (pp. 478–496). New York: Thieme.

    Google Scholar 

  • Gopal, K.V., Wu, C., Shreshta, B., Campbell, K. C. M., Moore, E. J., & Gross, G. W. (2012). D-Methionine protects against cisplatin-induced neurotoxicity in cortical networks Neurotoxicology and Teratology, 34(5), 495–504.

    Google Scholar 

  • Gratton, M. A., Salvi, R. J., Kamen, B. A., & Saunders, S. S. (1990). Interaction of cisplatin and noise on the peripheral auditory system. Hearing Research, 50, 211–223.

    Google Scholar 

  • Grunberg, S., Sonka, S., & Stevenson, L. (1989). Progressive parestesias after cessation of therapy with very high-dose cisplatin. Cancer Chemotherapy Pharmacology, 2, 62–64.

    Google Scholar 

  • Hamstra, D., Eisbruch, A., Naidu, M., Ramana, G., Sunkara, P., et al. (2010). Pharmacokinetic analysis of Phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clinical Cancer Research, 16(9), 2666–2676.

    Google Scholar 

  • Harned, T. M., Kalous, O., Neuwelt, A., Loera, J., Ji, L., et al. (2008). Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clinical Cancer Research, 14(2), 533–540.

    Google Scholar 

  • Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., et al. (2009). American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. Journal of Clinical Oncology, 27(1), 127–145.

    Google Scholar 

  • Hoskison, E., Daniel, M., Al-Zahid, S., Shakesheff, K. M., Bayston, R., & Birchall, J. P. (2013). Drug delivery to the ear. Therapeutic Delivery, 4(1), 115–124.

    Google Scholar 

  • Itoh, T., Terazawa, R., Kojima, K., Nakane, K., Deguchi, T., et al. (2011). Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free Radical Research, 45(9), 1033–1039.

    Google Scholar 

  • Jones, M. M., & Basinger, M. A. (1989). Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the Walker 256 carcinosarcoma. Anticancer Research, 9(6), 1937–1941.

    Google Scholar 

  • Jones, M. M., Basinger, M. A., & Holscher, M. A. (1991). Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity. Toxicology, 68(3), 227–247.

    Google Scholar 

  • Khan, A. B., D’Souza, B. J., Wharam, M. D., Champion, L. A., Sinks, L. F., et al. (1982). Cisplatin therapy in recurrent childhood brain tumors. Cancer Treatment Reports, 66(12), 2013–2020.

    Google Scholar 

  • Knight, K., Kraemer, D., & Neuwelt, E. (2005). Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. Journal of Clinical Oncology, 23, 8588–8596.

    Google Scholar 

  • Knight, K. R., Kraemer, D. F., Winter, C., & Neuwelt, E. A. (2007). Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. Journal of Clinical Oncology, 25(10), 1190–1195.

    Google Scholar 

  • Kopelman, J., Budnick, A., Sessions, R., Kramer, M., & Wong, G. (1988). Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancer and normal hearing. Laryngoscope, 98, 858–864.

    Google Scholar 

  • Kopke, R., Slade, M. D., Jackson, R., Hammill, T., Fausti, S., et al. (2015). Efficacy and safety of N-acetylcysteine in prevention of noise induced hearing loss: A randomized clinical trial. Hearing Research, 323, 40–50.

    Google Scholar 

  • Korver, K. D., Rybak, L. P., Whitworth, C. A., & Campbell, K. C. M. (2002). Round window application of D-methionine provides complete CDDP otoprotection. Otolaryngology–Head and Neck Surgery, 126(2), 683–689.

    Google Scholar 

  • Kujansuu, E., Rahko, T., Punnonen, R., & Karma, P. (1989). Evaluation of the hearing loss associated with cisplatin treatment by high-frequency audiometry. Gynecology Oncology, 33, 321–322.

    Google Scholar 

  • Laurell, G., & Pierre, P. V. (2015). Hearing loss after cisplatin: Oxidative stress pathways and potential for protection. In J. M. Miller, C. G. Le Prell, & L. P. Rybak (Eds.), Oxidative stress in applied basic research and clinical practice: Free radicals in ENT pathology (pp. 217–241). New York: Humana Press.

    Google Scholar 

  • Lewis, M. J., DuBois, S. G., Fligor, B., Li, X., Goorin, A., & Grier, H. E. (2009). Ototoxicity in children treated for osteosarcoma. Pediatric Blood Cancer, 52(3), 387–391.

    Google Scholar 

  • Li, Y., Womer, R., & Silber, J. (2004). Predicting cisplatin ototoxicity in children: Influence of age and the cumulative dose. European Journal of Cancer, 40, 2445–2451.

    Google Scholar 

  • Lippman, A., Helson, C., Helson, L., & Krakoff, I. (1973). Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemotherapy Reports, 1(57), 191–200.

    Google Scholar 

  • Lonsbury-Martin, B. L., & Martin, G. K. (1990). The clinical utility of distortion-product otoacoustic emissions. Ear and Hearing, 11, 144–154.

    Google Scholar 

  • Lonsbury-Martin, B. L., & Martin, G. K. (2001). Evoked otoacoustic emissions as objective screeners for ototoxicity. Seminars in Hearing, 22(4), 377–391.

    Google Scholar 

  • Lynch, E. D., & Kil, J. (2005). Compounds for the prevention and treatment of noise-induced hearing loss. Drug Discovery Today, 10(19), 1291–1298.

    Google Scholar 

  • Lynch, E. D., Gu, R., Pierce, C., & Kil, J. (2005). Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs, 16(5), 569–579.

    Google Scholar 

  • Martin, G. K., Ohlms, L. A., Franklin, D. J., & Lonsbury-Martin, B. L. (1990). Distortion product emissions in humans. III: Influence of sensorineural hearing loss. The Annals of Otology, Rhinology, and Laryngology (Suppl.), 147, 30–42.

    Google Scholar 

  • McHugh, P., Spanswick, V., & Hartley, J. (2001). Repair of DNA interstrand crosslinks: Molecular mechanisms and clinical relevance. The Lancet Oncology, 2(8), 483–490.

    Google Scholar 

  • Meech, R. P., Campbell, K. C. M., Hughes, L. P., & Rybak, L. P. (1998). A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hearing Research, 124, 44–59.

    Google Scholar 

  • Moroso, M., & Blair, R. L. (1983). A review of cis-platinum ototoxicity. Journal of Otolaryngology, 12, 365–369.

    Google Scholar 

  • Muldoon, L. L., Pagel, M. A., Kroll, R. A., Brummett, R. E., Doolittle, N. D., et al. (2000). Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clinical Cancer Research, 6(1), 309–315.

    Google Scholar 

  • Mulheran, M., & Degg, C. (1997). Comparison of distortion product OAE generation between a group requiring frequent gentamicin therapy and control subjects. British Journal of Audiology, 31, 5–9.

    Google Scholar 

  • NCT00652132. Cisplatin with or without sodium thiosulfate in treating young patients with stage I, stage II, or stage III childhood liver cancer. https://www.clinicaltrials.gov/ct2/show/NCT00652132. Accessed September 18, 2015.

  • NCT00716976. Sodium thiosulfate in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy. https://www.clinicaltrials.gov/ct2/show/NCT00716976. Accessed September 18, 2015.

  • NCT01345474. Phase 3 clinical trial: D-methionine to reduce noise-induced hearing loss (NIHL). https://www.clinicaltrials.gov/ct2/show/NCT01345374. Accessed September 18, 2015.

  • NCT01369641. The effect of sodium thiosulfate eardrops on hearing loss in patients who receive cisplatin therapy. https://www.clinicaltrials.gov/ct2/show/NCT01369641. Accessed September 18, 2015.

  • NCT01451853. SPI-1005 for prevention and treatment of chemotherapy induced hearing loss. https://www.clinicaltrials.gov/ct2/show/NCT01451853. Accessed September 18, 2015.

  • NCT02281006. Efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity. https://www.clinicaltrials.gov/ct2/show/NCT02281006. Accessed September 18, 2015.

  • Neuwelt, E. A., Brummett, R. E., Remsen, L. G., Kroll, R. A., Pagel, M. A., et al. (1996). In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Research, 56(4), 706–709.

    Google Scholar 

  • Nitz, A., Kontopantelis, E., Bielack, S., Koscielniak, E., Klingebiel, T., et al. (2013). Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncology Letters, 5(1), 311–315.

    Google Scholar 

  • Osterhammel, D. (1980). High frequency audiometry. Clinical aspects. Scandinavian Audiology, 9, 249–256.

    Google Scholar 

  • Otto, W. C., Brown, R. D., Gage-White, L., Kupetz, S., Anniko, M., et al. (1988). Effects of cisplatin and thiosulfate upon auditory brainstem responses of guinea pigs. Hearing Research, 35(1), 79–85.

    Google Scholar 

  • Peleva, E., Aloy, E., Carret, A. S., and Daniel, S. J. (2014). Hearing loss in a pediatric patient following cisplatin chemotherapy and subsequent exposure to excessive noise. International Journal of Pediatric Otorhinolaryngology, 78(12), 2301–2304.

    Google Scholar 

  • Plinkert, P. K., & Krober, S. (1991). Fruherkennung einer Cisplatin-Ototoxizitat durch evosierte otoakustische Emissionen. Laryngorhinootologie, 70, 457–462.

    Google Scholar 

  • Probst, R., Lonsbury-Martin, B. L., & Martin, G. K. (1991). A review of otoacoustic emissions. The Journal of the Acoustical Society of America, 20, 2021–2027.

    Google Scholar 

  • Ress, B. D., Sridhar, K. S., Balkany, T. J., Waxman, G. M., Stagner, B. B., & Lonsbury-Martin, B. L. (1999). Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Otolaryngology–Head and Neck Surgery, 121(6), 693–701.

    Google Scholar 

  • Rey, J. (2007). Pharmacodynamics and pharmacokinetics. In K. C. M. Campbell (Ed.), Pharmacology and ototoxicity for audiologists (pp. 10–18). Clifton Park, NY: Thompson Delmar Learning.

    Google Scholar 

  • Riga, M. G., Chelis, L., Kakolyris, S., Papadopoulos, S., Stathakidou, S., et al. (2013). Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: A feasible method with promising efficacy. American Journal of Clinical Oncology, 36(1), 1–6.

    Google Scholar 

  • Rosenberg, B., Vancamp, L., & Krigas, T. (1965). Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205, 698–699.

    Google Scholar 

  • Rosenberg, B., VanCamp, L., Trosko, J., & Mansour, V. (1969). Platinum compounds: A new class of potent antitumour agents. Nature, 222(5191), 385–386.

    Google Scholar 

  • Rybak, L. P., Huang, X., & Campbell, K. C. (2007). Cancer and ototoxicity of chemotherapeutics. In K. C. M. Campbell (Ed.), Pharmacology and ototoxicity for audiologists (pp. 138–162). Clifton Park, NY: Thomson Delmar Learning.

    Google Scholar 

  • Schmidt, C. M., Bartholomäus, E., Deuster, D., Heinecke, A., & Dinnesen, A.G. (2007). The “Muenster classification” of high frequency hearing loss following cisplatin chemotherapy. HNO, 55(4), 299–306.

    Google Scholar 

  • Sherman, S., Gibson, D., Wang, A., & Lippard, S. (1985). X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(pGpG))]. Science, 230(4724), 412–417.

    Google Scholar 

  • Stavroulaki, P., Apostolopoulos, N., Dinopoulo, D., Vossinakis, I., Tsakanikos, M., & Douniadakis, D. (1999). Otoacoustic emissions—an approach for monitoring aminoglycoside induced ototoxicity in children. International Journal of Pediatric Otorhinolaryngology, 50, 177–184.

    Google Scholar 

  • Stelmachowicz, P. G., Beauchaine, K. A., Kalberer, A., & Jesteadt, W. (1989). Normative thresholds in the 8–20 kHz range as a function of age. The Journal of the Acoustic Society of America, 86(4), 1384–1391.

    Google Scholar 

  • Stöhr, W., Langer, T., Kremers, A., Bielack, S., Lamprecht-Dinnesen, A., et al. (2005). German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology. Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system. Cancer Investigation, 23, 201–207.

    Google Scholar 

  • Taguchi, T., Nazneen, A., Abid, M., & Razzaque, M. (2005). Cisplatin associated nephrotoxicity and pathological events. Contributions to Nephrology, 148, 107–121.

    Google Scholar 

  • Thornton, A., & Raffin, M. J. M. (1977). Speech discrimination scores modeled as a binomial variable. Journal of Speech and Hearing Research, 21, 507–518.

    Google Scholar 

  • Whitney, K. A., Lysaker, P. H., Steiner, A. R., Hook, J. N., Estes, D. D., & Hanna, N. H. (2008). Is “chemobrain” a transient state? A prospective pilot study among persons with non-small cell lung cancer. Journal of Supportive Oncology, 6(7), 313–321.

    Google Scholar 

  • Wiley, T. L., Cruikshanks, K. J., Nondahl, D. M., Tweed, T. S., Klein, R., et al. (1998). Aging and high frequency hearing sensitivity. Journal of Speech, Language, and Hearing Research, 41, 1061–1072.

    Google Scholar 

  • World Health Organization (WHO). (1997). Report of the First Informal Consultation on Future Programme Developments for the Prevention of Deafness and Hearing Impairment.

    Google Scholar 

  • Yoo, J., Hamilton, S. J., Angel, D., Fung, K., Franklin, J., et al. (2014). Cisplatin otoprotection using transtympanic l-N-acetylcysteine: A pilot randomized study in head and neck cancer patients. Laryngoscope, 124(3), E87–E94.

    Google Scholar 

  • Zou, J., Sood, R., Ranjan, S., Poe, D., Ramadan, U. A, et al. (2012). Size-dependent passage of liposome nanocarriers with preserved posttransport integrity across the middle-inner ear barriers in rats. Otology & Neurotology, 33(4), 666–673.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, 801 N. Rutledge, Springfield, Illinois, 62794-9629, USA

    Kathleen C. M. Campbell & Daniel J. Fox

Authors
  1. Kathleen C. M. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen C. M. Campbell .

Editor information

Editors and Affiliations

  1. Callier Center for Communication Disorders, University of Texas at Dallas, Dallas, Texas, USA

    Colleen G. Le Prell

  2. Callier Center for Communication Disorders, University of Texas at Dallas, Dallas, Texas, USA

    Edward Lobarinas

  3. Department of Biology, University of Maryland, College Park, Maryland, USA

    Arthur N. Popper

  4. Marine Biological Laboratory, Woods Hole, Massachusetts, USA

    Richard R. Fay

Additional information

Compliance with Ethics Requirements

Kathleen Campbell is the sole inventor on the patents for D-methionine. Her patents belong to her employer SIU School of Medicine. She is also the cofounder and Chief Scientific Officer for MetArmor, Inc. which has licensed her patents from SIU.

Dr. Daniel Fox is currently the Program Manager for MetArmor team, however he had no financial affiliations during the creation of this chapter.

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Campbell, K.C.M., Fox, D.J. (2016). Cisplatin-Induced Hearing Loss. In: Le Prell, C., Lobarinas, E., Popper, A., Fay, R. (eds) Translational Research in Audiology, Neurotology, and the Hearing Sciences. Springer Handbook of Auditory Research, vol 58. Springer, Cham. https://doi.org/10.1007/978-3-319-40848-4_6

Download citation

Publish with us

Policies and ethics

Search

Navigation